

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2019/173744 A1

(43) International Publication Date
12 September 2019 (12.09.2019)

(51) International Patent Classification:

A61K 31/506 (2006.01) A61K 9/00 (2006.01)
A61P 27/14 (2006.01)

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2019/021402

(22) International Filing Date:

08 March 2019 (08.03.2019)

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(25) Filing Language:

English

(26) Publication Language:

English

Published:

— with international search report (Art. 21(3))

(30) Priority Data:

62/641,094 09 March 2018 (09.03.2018) US
62/663,999 27 April 2018 (27.04.2018) US

(71) Applicants: PORTOLA PHARMACEUTICALS, INC.

[US/US]; 270 E. Grand Ave., Suite 22, South San Francisco, California 94080 (US). ORA, INC. [US/US]; 300 Brickstone Square, 3rd Floor, Andover, Massachusetts 01810 (US).

(72) Inventors: PANDEY, Anjali; c/o Portola Pharmaceuticals,

Inc., 270 East Grand Ave., Suite 22, South San Francisco, California 94080 (US). CHAPIN, Matthew; c/o Ora, Inc., 300 Brickstone Square, 3rd Floor, Andover, Massachusetts 01810 (US). PATTERSON, Harold; c/o Ora, Inc., 300 Brickstone Square, 3rd Floor, Andover, Massachusetts 01810 (US). HSU, Yung Yueh; c/o Ora, Inc., 300 Brickstone Square, 3rd Floor, Andover, Massachusetts 01810 (US). ABELSON, Mark; c/o Ora, Inc., 300 Brickstone Square, 3rd Floor, Andover, Massachusetts 01810 (US).

(74) Agent: TANNER, Lorna L. et al.; Sheppard Mullin

Richter & Hampton LLP, 379 Lytton Avenue, Palo Alto, California 94301-1479 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: METHODS OF USE AND PHARMACEUTICAL COMPOSITIONS OF A SELECTIVE SYK INHIBITOR

(57) Abstract: Provided herein are methods of using Syk inhibitors, such as a selective Syk inhibitor, Compound 1 or a pharmaceutically acceptable salt thereof, in treating allergic and/or inflammatory diseases or conditions of the eye. Also provided is pharmaceutical compositions, in particular eyedrop ophthalmic compositions, comprising Compound 1 or a pharmaceutically acceptable salt thereof, useful in the methods.



WO 2019/173744 A1